Cencora Inc. stock gains after raising full-year EPS guidance
Published on 09/20/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora Inc. stock (ISIN US15135B1017) is trading at a firm valuation after the healthcare distributor raised its full-year adjusted earnings guidance on August 5, 2026 and reported double-digit EPS growth for fiscal third quarter 2026, with the shares recently changing hands at about 15.55 times forward earnings as of September 18, 2026.
Guidance raised on strong Q3 2026 figures
According to Yahoo Finance, Cencora reported results for its fiscal third quarter 2026, which ended on June 30, 2026, on August 5, 2026, posting revenue of USD 84.8 billion, up 5.1 percent from the same quarter a year earlier.
In the same report, adjusted earnings per share for fiscal Q3 2026 climbed 12.0 percent year on year to USD 4.48, highlighting that profit growth outpaced the already solid top-line expansion over the period, a combination investors often look for in the healthcare distribution sector.
On the back of these figures, management raised its outlook for adjusted EPS for the full fiscal year 2026 and now expects a range between USD 17.75 and USD 17.95, compared with a previously lower guidance range, as summarized by Yahoo Finance.
Analysts see EPS beating forecasts
Equity analysts tracking Cencora highlighted that the company beat consensus earnings expectations in fiscal Q3 2026. According to MarketBeat on September 20, 2026, Cencora reported quarterly EPS of USD 4.48, beating the analyst consensus forecast of USD 4.35 by USD 0.13 per share.
The same MarketBeat overview notes that fiscal Q3 2026 revenue of USD 84.75 billion modestly exceeded analyst expectations of USD 84.31 billion, and that quarterly revenue was up 5.1 percent compared with the prior-year quarter, confirming the growth trends reported by other outlets.
For the full fiscal year 2026, equities analysts covered by MarketBeat forecast that Cencora will post EPS of approximately USD 17.87, broadly in line with the company’s raised guidance range and underscoring market confidence in the earnings trajectory.
Valuation and recent share performance
From an investor perspective, valuation has become a key discussion point following the guidance increase. As outlined by Yahoo Finance, Cencora stock was trading at about 15.55 times forward earnings as of September 18, 2026, meaning investors were paying roughly USD 15.55 for each dollar of profit expected over the next 12 months.
Price data from a major charting portal show that Cencora shares trade on the New York Stock Exchange under the ticker COR and have posted sizable gains over recent periods. According to TradingView data as of September 19, 2026, the COR share price stood around USD 306.10, up 1.50 percent over the preceding 24 hours; over the past year, the stock delivered a gain of 29.93 percent, while the weekly change was 5.67 percent and the monthly change 5.52 percent, reflecting a sustained upward trend.
The same TradingView overview indicates that Cencora’s share price movements have been relatively low beta, with a beta coefficient of 0.18, and that the stock’s volatility stands at about 1.83 percent, a profile that may appeal to investors seeking exposure to healthcare distribution with more moderate market swings.
Dividend and shareholder returns
Besides earnings growth, Cencora also offers a modest dividend component in its total shareholder return. As noted by TradingView data retrieved on September 19, 2026, the most recent dividend per Cencora share was USD 0.55, and the trailing twelve-month dividend yield stood at around 0.73 percent, which is relatively low but consistent with the company’s focus on reinvesting cashflow and buying back shares.
Share repurchases have complemented the dividend in recent quarters. The analysis from Yahoo Finance points out that Cencora executed approximately USD 1 billion of share buybacks around the time of the fiscal Q3 2026 results, which can support EPS growth by reducing the share count and signal management confidence in the valuation.
Risk factors and investor considerations
Despite the strong numbers, investors should be aware of the risks inherent in Cencora’s business model. The MarketBeat earnings summary highlights that Cencora’s net margin in fiscal Q3 2026 was 0.79 percent and that return on equity stood at 125.45 percent, illustrating how thin margins and high leverage are typical features of large-scale pharmaceutical distribution and require ongoing operational discipline.
Revenue growth of 5.1 percent year on year in fiscal Q3 2026, while solid, remains dependent on the broader healthcare environment, prescription volumes and pricing, as described by MarketBeat, so shifts in regulation or reimbursement could affect future quarters.
Stock price as of recent trading
In New York Stock Exchange trading under the ticker COR, Cencora Inc. stock recently closed around USD 306.10, with that level recorded in price data as of September 19, 2026, and reflecting a daily gain of 1.50 percent in United States dollar terms. At this price, the shares stand well above their 52-week low while remaining below the 52-week high, consistent with the roughly 29.93 percent price increase over the past year reported by TradingView.
Cencora Inc. stock at a glance
- Company: Cencora Inc.
- ISIN: US15135B1017
- Ticker: COR
- Trading venue: NYSE
- Price (as of September 19, 2026): 306.10 USD
- Market capitalization: 0.73% dividend yield context (as of September 19, 2026)
- Sector / Industry: Healthcare / pharmaceutical distribution and services
- Index membership: S&P 500
